mirvetuximab soravtansinegemcitabineexatecanClone 65FDAplatinum-resistant ovarian cancerrecurrent diseaseepithelial ovarian cancersSanyou Biopharmaceuticals Laboratory Animal Ethics CommitteeSKOV3
…sis, achieved superior tumor growth inhibition and outperformed mirvetuximab soravtansine. Our data highlights the therapeutic potential and tolerability…